Nutriband increases existing credit line to $5 million usd for the development of its aversa(tm) platform towards fda submission

Company targeting fda submission in the first half of 2024 aversa ™ fentanyl is the flagship product of the company's aversa™ platform orlando, fl / accesswire / july 14, 2023 / nutriband inc. ("company") (nasdaq:ntrb)(nasdaq:ntrbw), a developer of transdermal pharmaceutical products, today announced that it has expanded its existing credit line facility to $5 million usd to fund the continued development and regulatory submission process for the company's patented lead product platform, aversa™ fentanyl, an abuse-deterrent fentanyl transdermal system. the company is targeting fda submission for aversa™ fentanyl in the first half of 2024.
NTRB Ratings Summary
NTRB Quant Ranking